Separase activity distribution can be a marker of major molecular response and proliferation of CD34<sup>+</sup> cells in TKI-treated chronic myeloid leukemia patients.

Spiess, Birgit; Kleiner, Helga; Flach, Johanna; Fabarius, Alice; Saussele, Susanne; Hofmann, Wolf-Karsten; Seifarth, Wolfgang

Separase activity distribution can be a marker of major molecular response and proliferation of CD34⁺ cells in TKI-treated chronic myeloid leukemia patients.

Spiess, Birgit; Kleiner, Helga; Flach, Johanna; Fabarius, Alice; Saussele, Susanne; Hofmann, Wolf-Karsten; Seifarth, Wolfgang.

Afiliação

Spiess B; Department of Hematology and Oncology, University Hospital Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. birgit.spiess@medma.uni-heidelberg.de.
Kleiner H; Hämatologie und Onkologie, III. Medizinische Klinik, Wissenschaftliches Labor, Universitätsklinikum Mannheim GmbH, Pettenkoferstraße 22, 68169, Mannheim, Germany. birgit.spiess@medma.uni-heidelberg.de.
Flach J; Department of Hematology and Oncology, University Hospital Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Fabarius A; Department of Hematology and Oncology, University Hospital Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Saussele S; Department of Hematology and Oncology, University Hospital Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Hofmann WK; Department of Hematology and Oncology, University Hospital Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Seifarth W; Department of Hematology and Oncology, University Hospital Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Ann Hematol ; 99(5): 991-1006, 2020 May.

Article em En | MEDLINE | ID: mdl-32253454

Assuntos

Antígenos CD34/metabolismo; Biomarcadores Tumorais/metabolismo; Proliferação de Células/efeitos dos fármacos; Leucemia Mielogênica Crônica BCR-ABL Positiva; Inibidores de Proteínas Quinases/administração & dosagem; Separase/metabolismo; Adolescente; Adulto; Idoso; Idoso de 80 Anos ou mais; Feminino; Proteínas de Fusão bcr-abl/metabolismo; Humanos; Leucemia Mielogênica Crônica BCR-ABL Positiva/tratamento farmacológico; Leucemia Mielogênica Crônica BCR-ABL Positiva/enzimologia; Leucemia Mielogênica Crônica BCR-ABL Positiva/patologia; Masculino; Pessoa de Meia-Idade

Palavras-chave

BCR-ABL1 expression; Chronic myeloid leukemia (CML); ESPL1/separase; Leukemic niche; Leukemic stem cell (LSC); Major molecular remission (MMR)

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mielogênica Crônica BCR-ABL Positiva / Biomarcadores Tumorais / Antígenos CD34 / Inibidores de Proteínas Quinases / Proliferação de Células / Separase Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google